Cargando…

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction

We evaluated safety, tolerability, pharmacokinetics (PKs), and pharmacodynamics of AZD4831, a novel oral myeloperoxidase (MPO) inhibitor, in a randomized, single‐blind, placebo‐controlled study, following once‐daily multiple ascending dosing to steady‐state in healthy subjects. Target engagement was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nelander, Karin, Lagerstrom‐Fermer, Maria, Amilon, Carl, Michaëlsson, Erik, Heijer, Maria, Kjaer, Magnus, Russell, Muir, Han, David, Lindstedt, Eva‐Lotte, Whatling, Carl, Gan, Li‐Ming, Ericsson, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212712/ https://www.ncbi.nlm.nih.gov/pubmed/32770730 http://dx.doi.org/10.1111/cts.12859

Ejemplares similares

Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers
por: Gan, Li‐Ming, et al.
Publicado: (2019)

Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction
por: Inghardt, Tord, et al.
Publicado: (2022)

Correction to “Discovery of AZD4831, a Mechanism-Based Irreversible Inhibitor of Myeloperoxidase, As a Potential Treatment for Heart Failure with Preserved Ejection Fraction”
por: Inghardt, Tord, et al.
Publicado: (2022)

Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability
por: Ericsson, Hans, et al.
Publicado: (2019)

Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor
por: Ericsson, Hans, et al.
Publicado: (2018)

Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects
por: Knöchel, Jane, et al.
Publicado: (2021)

Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD
por: Heerspink, Hiddo J.L., et al.
Publicado: (2021)

Regional differences and coronary microvascular dysfunction in heart failure with preserved ejection fraction
por: Erhardsson, Mikael, et al.
Publicado: (2023)

Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction
por: Prescott, Eva, et al.
Publicado: (2020)

Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS‐HFpEF study
por: Venkateshvaran, Ashwin, et al.
Publicado: (2022)

Myeloperoxidase, a possible biomarker for the early diagnosis of cardiac diastolic dysfunction with preserved ejection fraction
por: Coculescu, Bogdan Ioan, et al.
Publicado: (2018)

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study
por: Whittaker, Andrew, et al.
Publicado: (2019)

Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction
por: Chandramouli, Chanchal, et al.
Publicado: (2022)

Mitochondrial myopathy, dysmorphism, exercise-induced vomiting and tachycardia the mutation m.4831G > A()
por: Finsterer, Josef, et al.
Publicado: (2017)

Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study
por: Patel, Ravi B., et al.
Publicado: (2021)

The Synthetic Myeloperoxidase Inhibitor AZD3241 Ameliorates Dextran Sodium Sulfate Stimulated Experimental Colitis
por: Ahmad, Gulfam, et al.
Publicado: (2020)

Myeloperoxidase deficiency preserves vasomotor function in humans
por: Rudolph, Tanja K., et al.
Publicado: (2012)

Synthetic mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Design of a Phase 2a Clinical Trial
por: Anttila, Vesa, et al.
Publicado: (2020)

Therapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice
por: Koop, Anja Christina, et al.
Publicado: (2020)

Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial
por: Squire, Iain B., et al.
Publicado: (2022)

High Intensity Exercises in Heart Failure with Preserved Ejection Fraction
por: Herdy, Artur Haddad, et al.
Publicado: (2018)

Pharmacological myeloperoxidase (MPO) inhibition in an obese/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling
por: Piek, Arnold, et al.
Publicado: (2019)

Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients
por: Hage, Camilla, et al.
Publicado: (2020)

Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes
por: Ramachandra, Chrishan J A, et al.
Publicado: (2021)

Exercise echocardiography in aortic stenosis with preserved ejection fraction
por: Postolache, Adriana, et al.
Publicado: (2020)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

Myeloperoxidase in Health and Disease
por: Ortiz-Cerda, Tamara, et al.
Publicado: (2023)

A rare case of acquired myeloperoxidase deficiency
por: Melnik, Zuzana, et al.
Publicado: (2021)

Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
por: D’Amario, Domenico, et al.
Publicado: (2019)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
por: Gan, Li-Ming, et al.
Publicado: (2019)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Management of heart failure with preserved ejection fraction
por: Gard, Emma, et al.
Publicado: (2020)

Managing heart failure with preserved ejection fraction
por: Davidson, Alexander, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Comorbidities in heart failure with preserved ejection fraction
por: Deichl, Andrea, et al.
Publicado: (2022)

A myeloperoxidase precursor, pro-myeloperoxidase, is present in human plasma and elevated in cardiovascular disease patients
por: Khalilova, Irada S., et al.
Publicado: (2018)

Left atrial dilation in patients with heart failure and preserved ejection fraction: Value of CMR Simpson method
por: Vassiliou, Vassilis, et al.
Publicado: (2016)

Skeletal muscle phenotypic switching in heart failure with preserved ejection fraction
por: Saw, Eng Leng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_phmgukbqt53a2g7cd9phg5u5io